Eli Lilly says a closely watched combination obesity regimen significantly boosted weight loss in mid-stage U.S. testing.

The company announced the findings as drugmakers compete in the obesity treatment market.

The article says patients lost up to 25 percent of their body weight in trial evaluations.

It also says people with Type 2 diabetes shed up to 60 pounds during testing.

Researchers say the regimen might bring health benefits beyond weight loss, though those effects are not itemized.

The article says trials are moving toward larger safety and efficacy checks, with Phase 3 data still ahead.

Cited coverage names the drug retatrutide and says Lilly is preparing a next-generation obesity contest with phase 3 data.

Regulatory submissions are expected after those pivotal studies, according to the article.

Read the full story on Eli Lilly’s mid-stage obesity combination results and the reported weight-loss figures.